Cytogenetic risk categories in acute myeloid leukemia: A comparison between MRC (Medical Research Council) and SWOG (Southwest Oncology Group) models);Grupos de riesgo citogenético en la leucemia mieloide aguda: Comparación de los modelos adoptados por los grupos MRC (Medical Research Council, del Reino Unido) y SWOG (Southwest Oncology Group, de EE.UU.)

Medicina Clinica

Volumn 121, Issue 4, 2003, Pages 121-125

  Martín Ramos, María Luisa ^a   López Pastor, Margarita ^a   de la Serna Torroba, Javier ^a   Ayala, Rosa ^a   García Alonso, Luis ^b   Barreiro Miranda, Emilia ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Acute myeloid leukemia; Cytogenetic; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; FLUDARABINE; IDARUBICIN; RETINOIC ACID; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW; CANCER CLASSIFICATION; CANCER RECURRENCE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FREQUENCY ANALYSIS; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PATIENT CODING; PROGNOSIS; REGRESSION ANALYSIS; STANDARDIZATION; TREATMENT PLANNING; UNITED KINGDOM; UNITED STATES;

EID: 0042309633     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13049798     Document Type: Article

References (24)

1. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
2. Knapp W, Strobl H, Majidic O. Flow cytometric analysis of cell surface and intracellular antigens in leukemia diagnosis. Cytometry 1994;18:187-98.
3. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk- directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999;107:69-79.
4. Mrózek K, Heinonen K, De la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics of acute myeloid leukemia. Semin Oncol 1997; 24:17-31.
5. Mrózek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol 2000;72: 261-71.
6. Tallman M, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;37:1021-28.
7. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol 1997;24:92-102.
8. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the AML 10 trial. Blood 1998;92:2322-33.
9. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed AM, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Coperative Oncology Group study. Blood 2000;96:4075-83.
10. Mitelman F. ISCN: an International System for Human Cytogenetic Nomenclature. Basel, Swith zerland: Editorial S. Karger. Medical and Scientific Publishers. 1995.
11. Cox DR. Regression models and life tables. JR Stat Soc 1972;34:187-215.
12. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-72.
13. Second MIC Cooperative Study Group. Morphologic, Immunologic, and Cytogenetic (MIC) working classification of the acute myeloid leukemias. Cancer Genet Cytogenet 1988;30:1-15.
14. Hiddemann W, Kern W, Schooch C. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-76.
15. Granada I, Ribera JM, Millá F, Feliu E. Comparación de los resultados del estudio citogenético en las leucemias agudas mieloblásticas de novo y secundarias. Estudio de 69 pacientes. Med Clin (Barc) 1999;112:77-8.
16. Stasi R, Del Poeta G, Masi M, Tribalto M, Venditti A, Papa G, et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genetic Cytogenetic 1993;67:28.
17. Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev 1998;12:145-53.
18. Schoch C, Kern W, Krawitz P, Dugas M, Schnittger S, Haferlach T, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001;98:3500.
19. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1312-20.
20. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, Ras, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-95.
21. Bower M, Parry P, Carter M, Lillington DM, Amess J, Lister TA, et al. Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood 1994;84:3776-80.
22. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116-24.
23. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996;87:2870-7.
24. Martínez-Climent JA, Espinosa RI, Thirman MJ, Le Beaue MM, Rowley JD. Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias: identification of the t(9;11) as an indicator of long survival. J. Pediatr Hematol Onclo 1995; 17:277-83.